About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study of LY900014 in Participants With Type 1 Diabetes

NCT03214367·172 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Eli Lilly and Company

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year.
HbA1c of ≥7.0 and ≤9.5%.
Use insulin lispro, insulin aspart, or insulin glulisine as prandial insulin.
Use insulin glargine, insulin detemir, insulin degludec, or neutral protamine Hagedorn (NPH) insulin as basal insulin.

You may not be if

Have used other antihyperglycemic medications or therapies (inhaled, oral or injectable) within 90-days of screening.
Have had more than 1 severe hypoglycemic episode within 6 months of screening.
Have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening.
Have clinically significant gastrointestinal disease.

The record

StatusCompleted

PhasePhase 3

Taking part1,392

StartedJul 2017

UpdatedMay 1, 2020

Conditions

Type 1 Diabetes Mellitus

Where172

Internal Medicine Center LLC
Mobile, Alabama, United States
John Muir Physician Network Clinical Research Center
Concord, California, United States
AMCR Institute INC
Escondido, California, United States

Clareo Health | A Study of LY900014 in Participants With Type 1 Diabetes